Study Identifies New DNA Clues for Parkinson's Disease Risk
June 15, 2022 10:00 ET | Experimental Biology and Medicine
WASHINGTON, June 15, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 247, Issue 11, June, 2022) identifies a potential transcriptional profile to...
Alectos Logo big(1).jpg
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
June 06, 2022 07:30 ET | Alectos Therapeutics Inc.
Cambridge, Mass. and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) -- Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor...
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Eric Weisblum, CEO of Silo Pharma Inc.
May 18, 2022 08:17 ET | InvestorBrandNetwork (IBN)
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment...
Cutting-Edge Research Reveals Greater Insights into Parkinson’s Disease Progression
April 11, 2022 13:41 ET | Clinical Ink
Horsham, PA, April 11, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, today—World Parkinson’s Day—announces research that strengthens its standing as a critical...
IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.
March 30, 2022 08:30 ET | Silo Pharma Inc.
NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...
A Non-Invasive Digital Therapeutic, JOGO-Gx, Shows Early Success in Treating Parkinson's Disease Symptoms
March 17, 2022 09:00 ET | JOGO Health
BRIDGEWATER, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- JOGO-Gx, a non-invasive digital therapeutic built with AI and wearables that taps into the neuroplasticity of the brain using biofeedback, shows...
ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
March 10, 2022 07:00 ET | ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
January 25, 2022 07:00 ET | Athira Pharma, Inc.
BOTHELL, Wash., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
July 30, 2021 - ROSEN LOGO.jpg
ANVS BREAKING ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Annovis Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ANVS
August 19, 2021 18:15 ET | The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights
October 15, 2020 06:45 ET | Annovis Bio Inc.
BERWYN, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...